News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis Quarterly Shareholder Update and Investor Briefing
Pharmaxis Ltd (ASX: PXS) will release its Quarterly Shareholder Update on the morning of 31 July 2023.
Investors and analysts are invited to participate in a virtual investor briefing by the Company’s chief executive officer Mr Gary Phillips at 12.00 noon AEST on Monday 31 July 2023.
The event will consist of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees.
The event is free to attend, and investors should register in advance using the following registration link:
https://www.pharmaxis.com.au/investor-centre/investor-briefing/
Upon registration, instructions for joining the session will be sent via email.
To ensure as many questions as possible can be responded to in the allotted time, Pharmaxis welcomes investors to pre-submit questions by emailing them to: david.mcgarvey@pharmaxis.com.au
Pharmaxis to Present at MST Access Biotech ‘Hidden Gems’ Forum
Pharmaxis Ltd (ASX: PXS) chief executive officer Mr Gary Phillips will present commercial insights on the ground-breaking data from its studies in cancer and skin scarring at the MST Access webinar “Biotech ‘Hidden Gems’ Forum” on Thursday 20 July 2023. The webinar will commence at 10.00am AEST and will also feature presentations from Paradigm Bio Biopharmaceuticals Limited and BCAL Diagnostics Limited. The Pharmaxis presentation will commence at 11.00am AEST.
Shareholders and investors are invited to participate in this free event.
Investors should register in advance to participate using the following registration link:
https://mstfinancial-au.zoom.us/webinar/register/WN_6NK_VCkeSKWdBXgfY8kUZQ#/registration
Read full media release - pdf60% of Patients Show Improvement in Fibrosis in Pharmaxis Myelofibrosis Phase 2 Cancer Trial
- Final set of interim data from PXS-5505 trial in patients ineligible for a JAK inhibitor demonstrates improvements in fibrosis grade, excellent safety profile and promising signs of clinical activity.
- Protocol for next study cohort in combination with a JAK inhibitor submitted to FDA following positive type C meeting with start date scheduled later this year.
- Result reinforces skin scarring study outcome; Pharmaxis pan-LOX inhibitors demonstrate clear proof of concept in fibrosis